GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AFT Pharmaceuticals Ltd (OTCPK:AFTPF) » Definitions » Retained Earnings

AFT Pharmaceuticals (AFT Pharmaceuticals) Retained Earnings : $5.63 Mil (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is AFT Pharmaceuticals Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. AFT Pharmaceuticals's retained earnings for the quarter that ended in Mar. 2024 was $5.63 Mil.

AFT Pharmaceuticals's quarterly retained earnings increased from Mar. 2023 ($-3.23 Mil) to Sep. 2023 ($-2.69 Mil) and increased from Sep. 2023 ($-2.69 Mil) to Mar. 2024 ($5.63 Mil).

AFT Pharmaceuticals's annual retained earnings increased from Mar. 2022 ($-14.71 Mil) to Mar. 2023 ($-3.23 Mil) and increased from Mar. 2023 ($-3.23 Mil) to Mar. 2024 ($5.63 Mil).


AFT Pharmaceuticals Retained Earnings Historical Data

The historical data trend for AFT Pharmaceuticals's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AFT Pharmaceuticals Retained Earnings Chart

AFT Pharmaceuticals Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Retained Earnings
Get a 7-Day Free Trial Premium Member Only -29.85 -29.45 -14.71 -3.23 5.63

AFT Pharmaceuticals Quarterly Data
Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.71 -11.79 -3.23 -2.69 5.63

AFT Pharmaceuticals Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


AFT Pharmaceuticals  (OTCPK:AFTPF) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


AFT Pharmaceuticals (AFT Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
129 Hurstmere Road, Level 1, Takapuna, Auckland, NTL, NZL, 0622
AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Aqueous cream, Calci-tab, Maxigesic, Cromo-fresh, Crystaderm, Crytawash, Ellgy plus, Emulsifying ointment, and others. The group has four operating segments based on geographical location being, Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia which includes the sales and distribution activity relating to the Australian market.

AFT Pharmaceuticals (AFT Pharmaceuticals) Headlines